Promising clinical trials surrounding this compound, specifically the 120mg formulation referred to as ZPHC, reveal a considerable benefit on weight reduction and linked chronic factors. Researchers anticipate that this dual agonist , affecting both GLP-1 and GIP pathways , could offer a noteworthy advance in the management of overweight and relat